Frequently asked questions (FAQ)
General GcMAF questions
- Who is RCE?
- What is GcMAF?
- What are macrophages?
- Where are macrophages found in the body?
- How does GcMAF work?
Second Generation GcMAF
- What exactly is Second Generation GcMAF?
- How is this new GcMAF different from previous GcMAF preparations?
- How is GcMAF tested for activity?
- How stable is Second Generation GcMAF?
- How long have you been producing Second Generation GcMAF?
- Where do you produce Second Generation GcMAF?
- What other immunotherapies do you produce?
- What is Oral GcMAF?
- How is Oral GcMAF different from Second Generation GcMAF?
- Who can take Oral GcMAF?
- Is Oral GcMAF a replacement for Second Generation GcMAF?
- What are the commonly observed clinical effects of Oral GcMAF?
- Is Oral GcMAF tested for activity?
- How long does Oral GcMAF remain active?
- Where is Oral GcMAF produced?
- What diseases can benefit from GcMAF therapy?
- What is the usual dose of GcMAF therapy?
- How long should GcMAF therapy be continued?
- How is GcMAF administered?
- What tests should be done during GcMAF therapy?
- Are there any side effects with GcMAF?
- Can GcMAF be used with other conventional therapies?
- Are there any supplements I need to take with GcMAF?
- What should I avoid while using GcMAF?
- Is Nagalase testing necessary for GcMAF therapy?
Macrophages (Greek: big eaters) are cells originating from monocytes, a type of white blood cell found in the body. Macrophages function in both non-specific defense (innate immunity) as well as help initiate specific defense mechanisms (adaptive immunity) of vertebrate animals.
Their role is to phagocytize (engulf and then digest) cellular debris and pathogens, either as stationary or as mobile cells. They also stimulate lymphocytes and other immune cells to respond to pathogens. They are specialized phagocytic cells that attack foreign substances, infectious microbes and cancer cells through destruction and ingestion.
|A macrophage of a mouse stretching its “arms” (pseudopodia) to engulf two particles, possibly pathogens.|
Macrophages and other phagocytes are found in the following locations in the body:
|Main location||Types of phagocytes|
|Skin *||macrophages, resident Langerhans cells, dendritic cells, mast cells|
|Gut and intestinal Peyer’s patches *||macrophages|
|Lungs *||macrophages, monocytes, mast cells, dendritic cells|
|Bone marrow||macrophages, monocytes, sinusoidal cells, lining cells|
|Connective tissue||macrophages, monocytes, dendritic cells, histiocytes|
|Lymphoid tissue||macrophages, monocytes, dendritic cells|
|Spleen||macrophages, monocytes, sinusoidal cells|
* These locations offer the best sites for GcMAF administration. The skin by subcutaneous (SC) or intramuscular (IM) injection, the gut by oral administration and the lungs by inhalation using a nebulizer (such as Omron NE-U22V Portable Nebulizer).
Second Generation GcMAF
Second Generation GcMAF is made using a new and improved 2nd generation method of Gc-MAF production which is 10-20 times more concentrated and is more active and stable than other GcMAF that is currently available. Importantly, this much higher concentration GcMAF has been clinically demonstrated to be largely free of any side effects in the great majority of patients and is much more stable because it is resistant to oxidation.
First Generation GcMAF vs Saisei Mirai Second Generation GcMAF concentration
Our GcMAF is tested for macrophage phagocytic activity using mouse macrophages and sheep red blood cells at the University of Tokushima, Japan. The red blood cells are opsonized which marks them for ingestion and destruction by activated macrophages. Under the microscope this can be seen as purple areas in the clear cells. From this we calculate the Phagocytosis (ingestion) Index (PI).
See also Tests of Second Generation GcMAF for more details.
GcMAF is produced in Japan at the CPC in Osaka.
Our specialized sterile Cell Processing Center (CPC) and team of highly skilled laboratory staff
Carbon dioxide incubator
What other immunotherapies do you produce?
faq a In addition to GcMAF we produce NK cells (which we call Hyper T/NK Cell Therapy), lymphocytes and dendritic cells (DC). We are continuously researching and developing new immunotherapies for patients in collaboration with various universities in Japan.
Oral GcMAF made from bovine colostrum.
We have observed a number of common clinical effects from Oral GcMAF, such as:
- Improved sleep, more energy; reduced fatigue
- Improved digestion, reduced nocturnal urination
- Improved hair regrowth and reduced hair loss due to natural ageing
- Improved skin condition & smoothness
- Improved control or curing of infectious diseases such as virus, bacteria and other pathogens
- Reduced allergy symptoms, pollinosis and atopy
Gc-MAF and/or oral Colostrum MAF macrophage activation therapy is indicated in the treatment of any diseases where there is immune disfunction or where the immune system is compromised, such as:
|Cancer||Autoimmune diseases||Epstein-Barr Virus (EBV)|
|Hepatitis B virus (HBV)||Herpes Simplex virus (HSV)||Cystitis|
|Hepatitis C virus (HCV)||Multiple sclerosis (MS)||Urinary tract infection (UTI)|
|Autism Spectrum Disorders (ASD)||Rheumatoid arthritis (RA)||Endometriosis|
|Chronic Fatigue Syndrome (CFS)||Lyme disease (Lyme borreliosis)||IgA deficiency disorder|
|Myalgic Encephalomyelitis (ME)||Mycobacteria infections||Parkinson’s disease|
|Tuberculosis||Fibromyalgia||Human papillomavirus (HPV)|
|Lupus (Systemic lupus erythematosus, SLE)||HIV AIDS||Dengue fever|
|Pneumonia infection||Warts caused by viral infection||Norovirus|
|Malaria||Influenza virus (flu)||Herpes simplex virus (HSV)|
|Q fever (Coxiella burnetii)||Polycystic ovary syndrome (PCOS)||Chicken pox (varicella zoster virus)|
|Psoriasis||Respiratory tract infections||Ulcerative colitis, Crohn’s disease|
|Type 1 diabetes (T1DM), insulin-dependent diabetes (IDDM)||Type 1.5 diabetes, Latent autoimmune diabetes of adults (LADA)|
Cancer: For Second Generation GcMAF therapy we recommend 0.5 ml High Dose GcMAF (1500 ng/0.5 ml) 2-3 times a week in an integrative approach to treating cancer.
- More frequent dosing (daily or every second day) may be safely used with more advanced stage of disease, or initially in the treatment course.
- GcMAF may also be administered by intravenous (IV) injection, 0.5-1.0 ml 2-3 times per week in 20 ml or more saline, if deemed necessary, such as for advanced cases.
- We recommend IV GcMAF in addition to the usual IM/SC injections every week. These can be done on alternate days.
Other diseases (such as Autism, CFS, ME, Lyme disease): We recommend 0.25 ml High Dose GcMAF (1500 ng/0.5 ml) 2-3 times a week. Initial doses can start at 0.1 ml in the 1st week, 0.2 ml in the 2nd week, and 0.25 ml or 0.3 ml in the 3rd week. A higher dose of 0.5 ml 2-3 times per week may be required depending on the initial response. See our Autism Spectrum Disorders (ASD) page for more details on Autism.
GcMAF is administered by subcutaneous (SC) or intramuscular (IM) injection, 2-3 times per week (or as prescribed by the treating medical doctor) using a Size 26G x 1/2″ (0.45 x 13 mm) or Size 27G needle with a 2.5 ml or 1 ml syringe (single use, sterile disposable). The larger 2.5 ml syringe is easier to use due to the shorter plunger stroke distance necessary during injection. Diabetes needles may also be sufficient for administration of GcMAF, although these are a finer needle.
Treatment in our clinics has also been by intravenous (IV) and intratumoral (IT) injection, although IM and SC injection is by far the most common means of administration for most patients. Good aseptic technique using pharmaceutical ethanol (ethyl alcohol) to swab the top of vials before inserting needles is required when using the vials.
Various other methods of administration are possible:
Intravenous (IV) injection
GcMAF may be administered by intravenous (IV) infusion (drip) or by push IV. The usual dose is 0.5-1.0 ml 2-3 times per week in 20 ml or more saline. When given by push IV, 20 ml saline and GcMAF solution is administered in a 20 or 30 ml syringe for 3 minutes or longer.
Inhalation of GcMAF using a Nebulizer
Another option of administration is using a Nebulizer to activate macrophages in the bronchus-associated lymphoid tissue (BALT) of the lungs, for example, using a device such as the Omron NE-U22 Portable Nebuliser. This method of administration is particularly well suited to diseases of the lungs where local administation can have greater effect.
Oral administration using Colostrum MAF in Enteric capsules
RCE Oral Colostrum MAF in Enteric capsules provides another means of administation in the Gut Associated Lymphoid Tissue (GALT).
When we swallow Colostrum MAF orally by mouth inside the Enteric capsule (which doesn’t get digested in the acid environment of the stomach), the Colostrum MAF reaches the gut and activates macrophages in the Peyer’s Patches in the Gut Associated Lymphoid Tissue (GALT). The gut-associated lymphoid tissue accounts for about 70 % of our body’s immune system. Oral administration is best on an empty stomach before food in the morning, before bedtime or about 30 minutes before meals to allow quicker passage of the capsule through the stomach to the gut.
Macrophages are abundant in the Peyer’s patches of the intestines.
Oral administration using Colostrum MAF powder in the mouth
In the mouth and throat there is the lymphoid tissue which contains macrophages. When we administer oral Colostrum MAF powder by opening the capsules and putting the powder in our mouth for 15-20 minutes, or longer, these macrophages become activated. It’s also possible that some GcMAF is absorbed sublingually through the blood vessels in the mouth, however the activation of macrophages in the lymphoid tissue of the throat is believed to be the most important method. Lymphoid tissue is the part of the body’s immune system that is important for the immune response and helps protect it from infection and foreign bodies. For example, people who suffer from Immunoglobulin A (IgA) and Immunoglobulin M (IgM) deficiency can benefit from this form of administration.
How long should GcMAF therapy be continued?
One course of High Dose GcMAF is usually expected to be 48 doses for 6 months. Additional courses may be required depending on stage and type of disease, and based on disease symptoms, pathology and progress of improvement. Treatment with GcMAF should be continued as long as necessary while disease is present. Long term maintenance doses of GcMAF may be required depending on the type of disease. Maintenance doses are usually once a week or every 2 weeks administration.
As a general note, macrophage activation is always necessary for the effective functioning of the immune system to stay well and disease-free. GcMAF therapy should continue while there is disease present and for a period after to reduce the chance of recurrence for prevention.
We recommend checking tumor markers and regular MRI, PET and CT scans.
Monocyte Count: A patients monocyte count will generally rise in the early stages of GcMAF treatment and indicates a response to GcMAF.
Increase in Monocyte percentage with High Dose GcMAF therapy
Increase in Monocyte number with High Dose GcMAF therapy
- Example of monocyte count of Stage 4 Breast Cancer patient taking 0.5 ml High Dose GcMAF (1500 ng/0.5 ml) twice weekly by intramuscular injection during cancer treatment.
Generally, yes. GcMAF can be safely used with a wide variety of other standard treatments and drugs to improve their effect. We refer to this as multimodality integrative medicine. Some therapies for cancer such as chemotherapy will reduce immune activity which will have some impact on GcMAF, however chemotherapy effectiveness can be increased in combination with GcMAF. Radiation for cancer has less negative impact on the immune system and the cancer killing effects helps macrophages to target the tumors and destroy it.
In combination with anti-cancer drugs and radiation therapy (radiotherapy) is possible. For maximum effect and benefit from GcMAF, administer a few days apart from chemotherapy. Radiation therapy does not have significant effects on Gc-MAF, so both can be used together at any time. In our clinical experience we have observed significant cancer killing effects from GcMAF combined with palliative radiotherapy in patients who have had significant prior treatment with chemotherapy. See our Case Reports for more details on this multimodality integrative treatment.
Ordering and Shipping